Member Info for Bullishbearish

Stock can be held in numerous places in different nominees and still have the same beneficial owner
However if your accumulative holding is more than 3% you have to put out a TR1

It is a fund to fund
It was done at the middle price at the time

its a fund to fund

fund to fund

Oliver Stansfield has agreed to subscribe for, in aggregate, 367,584 Placing Shares representing a cash subscription of £25,730.88. Oliver Stansfield currently holds 1,132,416 Ordinary Shares, representing 5.2% of the Company's issued share capital and following Admission will hold 1,500,000 Ordinary Shares, representing 5.5% of the Company's issued share capital. However, in the 12 months prior to the Placing, Oliver Stansfield, alongside his former employer, Brandon Hill Capital, collectively held over 10% of the Company's current issued share capital. Accordingly, under AIM Rule 13 he and Brandon Hill Capital are still deemed to be a related party by virtue of the combined holding.

Just read the last update on the placing from Dec its all there

Oliver stansfield owns over 5% and if you look at the last placing in December it shows he is the broker to the company

Same here Esquimo

The broker behind this wont allow it to go under imoh hes one of the main holders

Well until you see one of the main holders exiting I def wont be selling as they say its not over until the fat lady sings and she isnt yet!

full of good news saus

Did you see this Ray?

ow.ly/MNCu50Nmkzm #weareHInM

Professor Jane Eddleston, Group Medical Director for Manchester University NHS Foundation Trust, said: “Delivering earlier and more accurate detection, diagnosis, and prognosis, through collaboration, is key to tackling the health inequalities across Greater Manchester. Through our clinical research excellence and joint working with our city-region health innovation accelerator colleagues and strategic global corporate partners we will be able to identify the most prevalent issues affecting our communities and develop targeted patient-centred care and treatment.”

Professor Graham Lord, Vice-President and Dean of the Faculty of Biology, Medicine and Health at the University of Manchester, said: “We are delighted that our city region has been recognised as a powerhouse for healthcare and life sciences innovation and proud of The University of Manchester’s part in this success. The innovation accelerator programme has great potential to transform healthcare for the better in our region and more generally.”

In addition, a programme to develop a pipeline of new genomic technologies will be established, in collaboration with the University of Manchester. The Development and Validation of Technology for Time Critical Genomic Testing (DEVOTE) Programme will bring together academic, industry and clinical partners from across the region to deliver enhanced genomic diagnostics to prevent stroke; rapid genetic point of care devices to detect genetic changes; and the development of ‘pharmacogenetic passport’ to optimise precision medicines for patients.

Bill Newman, Professor of Translational Genomic Medicine at UoM, Consultant in Genomic Medicine at MFT, and a researcher with the National Institute for Health and Care Research (NIHR) Manchester BRC, said: “This is a great opportunity to enhance GM’s status as a world leader in creating genetic tests that can give rapid results in minutes. We expect that the DEVOTE projects will lead to the adoption of new tests by the NHS to make drug prescription safer and more effective. This will be good for patients and good for GM by creating jobs and a centre for investment in this cutting-edge science.”
Add to that that some of the above has commented on Gdr tweets over the last few months so unless I am Putting 2 and 2 and coming up with 5 there’s a good chance that it’s us. At least that’s my personal view .

They could have done that twice already and haven’t .
The company could use a platform like primary bid if it was say 50 and offer at a 20% discount to general public and existing holders .
Chances are if they have a bit of news like we are getting grant funding and the NHS have placed an order I reckon they would get the cash they may or may not need.EASILY.
I personally think the company has not raised because they know what’s coming.

Well paddy if that happens you will be talking about a raise at a higher level than now .
So if the stock was 50 you would expect a discount of say 20% which equates to a higher price than today’s close .

They could have raised easily over the last few months and chose not to ,ask yourself why not!

We have a few new ones talking about placing etc ,at least it’s not the same ones who said it at 8,10,12 before it went to 48p.
Grant funding according to the weekends press could be forthcoming .
We know Nice approval is likely next week and we have distributors in place across the world to sell our life changing kit into their respective healthcare situations.
Likely our own NHS will roll this out as the cost savings to them is significant .
All in all it’s healthy retrace but the danger for those trading it is that maybe the next spike won’t have a pullback .

? The big seller is out

BigAl some fair points made there
So grant funding could be waiting in the wings and/or someone from big pharma or similar wants to take a decent position either will do away with the need for a placing imoh.
Mr Budd could be playing a blinder here and catch a few out

Maybe just maybe before any award of grant funding is made they would need to have NICE approval in full.
And maybe Mr Budd has already been told what to expect and maybe he knows he might not need to raise any cash after ALL?
Just my personal view

ow.ly/MNCu50Nmkzm #weareHInM
Professor Jane Eddleston, Group Medical Director for Manchester University NHS Foundation Trust, said: “Delivering earlier and more accurate detection, diagnosis, and prognosis, through collaboration, is key to tackling the health inequalities across Greater Manchester. Through our clinical research excellence and joint working with our city-region health innovation accelerator colleagues and strategic global corporate partners we will be able to identify the most prevalent issues affecting our communities and develop targeted patient-centred care and treatment.”

Professor Graham Lord, Vice-President and Dean of the Faculty of Biology, Medicine and Health at the University of Manchester, said: “We are delighted that our city region has been recognised as a powerhouse for healthcare and life sciences innovation and proud of The University of Manchester’s part in this success. The innovation accelerator programme has great potential to transform healthcare for the better in our region and more generally.”

In addition, a programme to develop a pipeline of new genomic technologies will be established, in collaboration with the University of Manchester. The Development and Validation of Technology for Time Critical Genomic Testing (DEVOTE) Programme will bring together academic, industry and clinical partners from across the region to deliver enhanced genomic diagnostics to prevent stroke; rapid genetic point of care devices to detect genetic changes; and the development of ‘pharmacogenetic passport’ to optimise precision medicines for patients.

Bill Newman, Professor of Translational Genomic Medicine at UoM, Consultant in Genomic Medicine at MFT, and a researcher with the National Institute for Health and Care Research (NIHR) Manchester BRC, said: “This is a great opportunity to enhance GM’s status as a world leader in creating genetic tests that can give rapid results in minutes. We expect that the DEVOTE projects will lead to the adoption of new tests by the NHS to make drug prescription safer and more effective. This will be good for patients and good for GM by creating jobs and a centre for investment in this cutting-edge science.”